Kami Maddocks News Today

But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question

'Safety profile is one of the real advantages' of non-covalent BTK inhibitor, says panelist

Study results show impressive efficacy, favorable safety profile in the second line

Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study

But experts aren't sure where it would fit in with currently approved bispecifics

Bispecific antibody also shows high response rates in frontline setting

Efforts to widen the treatment armamentarium for patients with mantle cell lymphoma have been thwarted by increased toxicities and resistance mechanisms with effective therapies such as BTK inhibitors.

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.